The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Open accessAbstract
Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-β precursor protein gene (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-β(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3β (aGSK-3β). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) and aGSK-3β levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-β, in GSK-3β activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“iPSC-derived neurons from individuals with AD exhibit increased production of Aβ42, active GSK-3β, phosphorylated tau, endosomal abnormalities, and oxidative stress (12–17)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but late-stage neuropathological features, such as formation of insoluble tau and neurodegeneration have not been reported.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, neuronal endosomal swelling has been classed as an early hallmark of Alzheimer's disease indicative of a perturbation in endosomal cargo sorting [8,9,56].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“pThr231Tau accumulates in APP duplication (APPdp) iPSC-derived FAD neurons (Israel et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
In the citing paper
“Several studies related to neurological disease successfully reverted a disease-associated cellular phenotype in patient-derived cells by correcting the disease-associated mutation, for example in the MAPT gene106,107.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [106]
In the citing paper
“Multiple groups have characterized iPSC lines from donor cells from FAD and sAD patients, which show increased production of Aβ, particularly Aβ42, and tau hyperphosphorylation in comparison to iPSCs derived from age-matched non-demented controls [66, 82, 101, 175].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
In the citing paper
“Some iPSC lines also have evidence of additional AD-associated pathology such as increased activation of GSK3β [66], increased number of large endosomes [66], and accumulation of intraneuronal Aβ oligomers [82].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liang, Q., Fujita, R., Yamashita, T., Angulo, S. L., Rhinn, H., Rhee, D. B., Doege, C. A., Chau, L., Aubry, L., Vanti, W. B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.007 · Cited by 231
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
Cited by
Sorted by citations
Items 501–600 of 1,002
Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?
Rodríguez-Jiménez, F. J., Ureña‐Peralta, J. R., Jendelová, P., & Erceg, S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.006 · Cited by 33
Assessment of human pluripotent stem cells with PluriTest
Müller, F.-J. (2014) · StemBook · doi:10.3824/stembook.1.84.1 · Cited by 28
Yasui, T., Uezono, N., Nakashima, H., Noguchi, H., Matsuda, T., Noda-Andoh, T., Okano, H., & Nakashima, K. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.05.001 · Cited by 27
Induced Pluripotent Stem Cells
Chang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T., Harn, H., & Lin, S. (2018) · Cell Transplantation · doi:10.1177/0963689718775406 · Cited by 31
Guix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 30
Sproul, A. A. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.007 · Cited by 31
Wang, W., Li, M., Wei, Z., Wang, Z., Bu, X., Lai, W., Yang, S., Gong, H., Zheng, H., Wang, Y., et al. (2014) · Analytical Chemistry · doi:10.1021/ac500465e · Cited by 30
Induced Pluripotent Stem Cells
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Lv, S., He, E., Luo, J., Liu, Y., Liang, W. J., Xu, S., Zhang, K., Yang, Y. F., Wang, M., Song, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202301828 · Cited by 32
Novel Insights into Disease Modeling Using Induced Pluripotent Stem Cells
Egashira, T., Yuasa, S., & Fukuda, K. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00960 · Cited by 30
Patient-derived stem cells: pathways to drug discovery for brain diseases
Mackay‐Sim, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00029 · Cited by 30
Trevisan, M., Sinigaglia, A., Desole, G., Berto, A., Pacenti, M., Palù, G., & Barzon, L. (2015) · Viruses · doi:10.3390/v7072800 · Cited by 28
Disease modelling using human iPSCs
Chamberlain, S. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw209 · Cited by 28
A new era of disease modeling and drug discovery using induced pluripotent stem cells
Suh, W. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0871-0 · Cited by 29
García‐León, J. A., Vitórica, J., & Gutiérrez, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0520 · Cited by 30
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 31
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases
Trudler, D., Ghatak, S., & Lipton, S. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158196 · Cited by 30
Almenar‐Queralt, A., Falzone, T. L., Shen, Z., Lillo, C., Killian, R. L., Arreola, A. S., Niederst, E. D., Ng, T. K. S., Kim, S. N., Briggs, S. P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1503-13.2014 · Cited by 30
Self-citationFroestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Xu, D. C., Sas‐Nowosielska, H., Donahue, G., Huang, H., Pourshafie, N., Good, C. R., & Berger, S. L. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01696-6 · Cited by 35
A CRISPR Approach to Neurodegenerative Diseases
Kampmann, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.04.003 · Cited by 27
Acun, A., & Zorlutuna, P. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.06.023 · Cited by 30
Caneus, J., Akanda, N., Rumsey, J. W., Guo, X., Jackson, M., Long, C. J., Sommerhage, F., Georgieva, S., Kanaan, N. M., Morgan, D., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12029 · Cited by 29
Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 28
Animal and Cellular Models of Alzheimer’s Disease: Progress, Promise, and Future Approaches
Trujillo‐Estrada, L., Sánchez‐Mejías, E., Sanchez-Varo, R. M., García‐León, J. A., Nuñez‐Diaz, C., Dávila, J. C., Vitórica, J., LaFerla, F. M., Moreno‐González, I., Gutiérrez, A., et al. (2021) · The Neuroscientist · doi:10.1177/10738584211001753 · Cited by 30
Modeling the Human Brain With ex vivo Slices and in vitro Organoids for Translational Neuroscience
Nogueira, G. O., Garcez, P. P., Bardy, C., Cunningham, M. O., & Sebollela, A. S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.838594 · Cited by 30
Self-citationNew approaches for direct conversion of patient fibroblasts into neural cells
Gopalakrishnan, S., Hor, P., & Ichida, J. K. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.012 · Cited by 28
Stem cells and the treatment of Parkinson's disease
Ali, F. R., Stott, S., & Barker, R. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.017 · Cited by 29
The Use of Induced Pluripotent Stem Cell Technology to Advance Autism Research and Treatment
Acab, A., & Muotri, A. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0354-x · Cited by 31
Direct somatic lineage conversion
Tanabe, K., Haag, D., & Wernig, M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0368 · Cited by 29
Promising Therapies for Alzheimer';s Disease
Confaloni, A., Tosto, G., & Tata, A. M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160215154218 · Cited by 29
Convergent molecular defects underpin diverse neurodegenerative diseases
Tofaris, G. K., & Buckley, N. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316988 · Cited by 30
Thiamine deficiency contributes to synapse and neural circuit defects
Yu, Q., Liu, H., Sang, S., Chen, L., Zhao, Y., Wang, Y., & Zhong, C. (2018) · Biological Research · doi:10.1186/s40659-018-0184-5 · Cited by 28
Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells
Naphade, S. B., Tshilenge, K., & Ellerby, L. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00810-8 · Cited by 30
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Rizzo, S. J. S., Territo, P. R., Arnold, S. E., Ballard, C. G., Beher, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14250 · Cited by 27
van den Hurk, M., & Bardy, C. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.108350 · Cited by 28
Self-citationNguyen, V. T. T., König, S., Eggert, S., Endres, K., & Kins, S. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0214 · Cited by 28
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 30
Genomics in Neurological Disorders
Han, G., Sun, J., Wang, J., Bai, Z., Song, F., & Lei, H. (2014) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2014.07.002 · Cited by 29
Steinberg, K. M., Ramachandran, D., Patel, V. C., Shetty, A. C., Cutler, D. J., & Zwick, M. E. (2012) · Molecular Autism · doi:10.1186/2040-2392-3-8 · Cited by 30
Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis
Ziff, O. J., & Patani, R. (2018) · Aging Cell · doi:10.1111/acel.12862 · Cited by 27
Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26
Modeling Alzheimer’s disease using human cell derived brain organoids and 3D models
Fernandes, S., Revanna, J. S., Pratt, J. M., Hayes, N., Marchetto, M. C., & Gage, F. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1434945 · Cited by 33
Self-citationInduced Pluripotent Stem Cells to Model and Treat Neurogenetic Disorders
Wang, H., & Doering, L. C. (2012) · Neural Plasticity · doi:10.1155/2012/346053 · Cited by 26
Cavalli, E., Battaglia, G., Basile, M. S., Bruno, V., Petralia, M. C., Lombardo, S. D., Pennisi, M., Kalfin, R. E., Tancheva, L. P., Fagone, P., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10030166 · Cited by 26
Frankowski, H., Yeboah, F., Berry, B. J., Kinoshita, C., Lee, M., Evitts, K. M., Davis, J., Kinoshita, Y., Morrison, R. S., & Young, J. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052526 · Cited by 26
Marei, H. E. S., Khan, M. U. A., & Hasan, A. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00504-2 · Cited by 27
Familial Alzheimer’s disease modelling using induced pluripotent stem cell technology
Mohamet, L. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i2.239 · Cited by 25
Liang, F., Zhang, Y., Hong, W., Dong, Y., Xie, Z., & Quan, Q. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00320 · Cited by 26
Höfling, C., Morawski, M., Zeitschel, U., Zanier, E. R., Moschke, K., Serdaroglu, A., Canneva, F., von Hörsten, S., Simoni, M. G. D., Forloni, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12508 · Cited by 28
Zhou, Y., Xu, Z., Yu, Y., Cao, J., Qiao, Y., Qiao, H., & Suo, G. (2019) · Molecular Omics · doi:10.1039/c9mo00129h · Cited by 26
Astrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Wang, W., Mutka, A., Zmrzljak, U. P., Rozman, D., Tanila, H., Gylling, H., Remes, A. M., Huttunen, H. J., & Ikonen, E. (2013) · The FASEB Journal · doi:10.1096/fj.13-239301 · Cited by 26
Self-citationToward pluripotency by reprogramming: mechanisms and application
Wang, T., Warren, S. T., & Jin, P. (2013) · Protein & Cell · doi:10.1007/s13238-013-3074-1 · Cited by 26
Advances in Reprogramming-Based Study of Neurologic Disorders
Nityanandam, A., & Baldwin, K. K. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0044 · Cited by 25
Romano, G., Morales, F., Marino, I. R., & Giordano, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24437 · Cited by 25
Cell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain
López-León, M., Outeiro, T. F., & Goya, R. G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.002 · Cited by 27
Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 25
Sabouni, N., Marzouni, H. Z., Palizban, S., Meidaninikjeh, S., Kesharwani, P., Jamialahmadi, T., & Sahebkar, A. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2141755 · Cited by 27
Complexity of Sex Differences and Their Impact on Alzheimer’s Disease
Kadlecová, M., Freude, K., & Haukedal, H. (2023) · Biomedicines · doi:10.3390/biomedicines11051261 · Cited by 27
Benwood, C., Walters-Shumka, J., Scheck, K., & Willerth, S. (2023) · Bioelectronics in Medicine · doi:10.1186/s42234-023-00112-7 · Cited by 26
Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration
Cooper, D. J., Zunino, G., Bixby, J. L., & Lemmon, V. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.07.001 · Cited by 24
Back to the origins: Human brain organoids to investigate neurodegeneration
Faravelli, I., Costamagna, G., Tamanini, S., & Corti, S. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146561 · Cited by 25
Bioengineered stem cells in neural development and neurodegeneration research
Yuan, S. H., & Shaner, M. A. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.04.002 · Cited by 24
Self-citationZhang, W., Jiao, B., Zhou, M., Zhou, T., & Shen, L. H. (2016) · Stem Cells International · doi:10.1155/2016/7828049 · Cited by 26
iPS Cells—The Triumphs and Tribulations
Sharma, R. (2016) · Dentistry Journal · doi:10.3390/dj4020019 · Cited by 24
Animal Models of Alzheimer’s Disease
Newman, M., Kretzschmar, D., Khan, I., Chen, M., Verdile, G., & Lardelli, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00040-1 · Cited by 25
Uliassi, E., Gandini, A., Perone, R. C., & Bolognesi, M. L. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0038 · Cited by 24
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24
Drabik, K., Malińska, D., Piecyk, K., Dębska–Vielhaber, G., Vielhaber, S., Duszyński, J., & Szczepanowska, J. (2021) · Antioxidants · doi:10.3390/antiox10060938 · Cited by 24
Microfluidic Platforms to Unravel Mysteries of Alzheimer’s Disease: How Far Have We Come?
Prasanna, P., Rathee, S., Rahul, V., Mandal, D., Goud, M. S. C., Yadav, P., Hawthorne, S. J., Sharma, A., Gupta, P. K., Ojha, S. K., et al. (2021) · Life · doi:10.3390/life11101022 · Cited by 25
Chaves, R. S., Tran, M., Holder, A. R., Balcer, A. M., Dickey, A. M., Roberts, E. A., Bober, B. G., Gutierrez, E., Head, B. P., Groisman, A., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2553-20.2021 · Cited by 23
Self-citationDefective proteostasis in induced pluripotent stem cell models of frontotemporal lobar degeneration
Mahali, S., Martinez, R., King, M., Verbeck, A., Harari, O., Benitez, B. A., Horie, K., Sato, C., Temple, S., & Karch, C. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02274-5 · Cited by 33
Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer’s Disease from 2004 to 2022
Wang, R., Zhu, Y., Qin, L.-F., Xu, Z., Gao, X.-R., Liu, C., Xu, G., & Chen, Y. (2023) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000528886 · Cited by 24
Cell type and sex specific mitochondrial phenotypes in iPSC derived models of Alzheimer’s disease
Flannagan, K., Stopperan, J. A., Hauger, B. M., Troutwine, B., Lysaker, C. R., Strope, T. A., Csikós, V., Gilmore, C. A., Swerdlow, N., Draper, J. M., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1201015 · Cited by 24
Lavekar, S. S., Harkin, J., Hernandez, M., Gomes, C., Patil, S., Huang, K.-C., Puntambekar, S. S., Lamb, B. T., & Meyer, J. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-40382-4 · Cited by 24
Induced pluripotent stem cells in research and therapy.
Teoh, H.-K., & Cheong, S. (2012) · PubMed · Cited by 24
Implications of aneuploidy for stem cell biology and brain therapeutics
Devalle, S., Sartore, R., Paulsen, B. S., Borges, H. L., Martins, R. A. P., & Rehen, S. K. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00036 · Cited by 24
Xie, Y., & Zhang, R. X. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1989-9 · Cited by 24
The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside
Xie, N., & Tang, B. (2016) · Stem Cells International · doi:10.1155/2016/6484713 · Cited by 25
Massa, M., Gisevius, B., Hirschberg, S., Hinz, L., Schmidt, M., Gold, R., Prochnow, N., & Haghikia, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155274 · Cited by 22
Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome
Botté, A., & Potier, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.002 · Cited by 22
Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises
Argentati, C., Tortorella, I., Bazzucchi, M., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10010008 · Cited by 24
Shum, C., Macedo, S. C., Warre-Cornish, K. M., Cocks, G. D., Price, J., & Srivastava, D. P. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.06.014 · Cited by 24
Wang, J., Fourrière, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 26
Modeling heart disease in a dish: From somatic cells to disease-relevant cardiomyocytes
Zanella, F., Lyon, R. C., & Sheikh, F. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2013.06.002 · Cited by 23
Genome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 23
Self-citationMorel, G., Chiavellini, P., Canatelli-Mallat, M., Lehmann, M., & Goya, R. G. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320966 · Cited by 24
Milky, B., Zabolocki, M., Al‐Bataineh, S. A., van den Hurk, M., Greenberg, Z., Turner, L., Mazzachi, P., Williams, A., Illeperuma, I., Adams, R., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.01.013 · Cited by 24
Self-citationAmbroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model
Yang, S. Y., Taanman, J., Gegg, M. E., & Schapira, A. H. V. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac038 · Cited by 23
Qu, W., Canoll, P., & Hargus, G. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.006 · Cited by 24
Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC‐Based Models
Fernández‐Santiago, R., & Ezquerra, M. (2015) · Stem Cells International · doi:10.1155/2016/9464591 · Cited by 24
Instant Neurons: Directed Somatic Cell Reprogramming Models of Central Nervous System Disorders
Liang, Q., Inoue, K., & Abeliovich, A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.027 · Cited by 22
iPSCs to the Rescue in Alzheimer's Research
Choi, S. H., & Tanzi, R. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.02.011 · Cited by 23
Orack, J. C., Deleidi, M., Pitt, D., Mahajan, K. R., Nicholas, J. A., Boster, A. L., Racke, M. K., Comabella, M., Watanabe, F., & Imitola, J. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0133 · Cited by 23
Aigner, S., Heckel, T., Zhang, J. D., Andreae, L. C., & Jagasia, R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3332-1 · Cited by 25
Amato, P., Daar, J., Francis, L., Klipstein, S., Ball, D., Rinaudo, P., Rajovic, A., Palmore, M., Tipton, S., Coutifaris, C., et al. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.012 · Cited by 25
Cellular reprogramming: a new approach to modelling Parkinson's disease
Hartfield, E. M., Fernandes, H. J. R., Vowles, J., Cowley, S. A., & Wade‐Martins, R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120159 · Cited by 23
Li, M., Pehar, M., Liu, Y., Bhattacharyya, A., Zhang, S., O’Riordan, K. J., Bürger, C., D'adamio, L., & Puglielli, L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.021 · Cited by 24
Human stem cell models of dementia
Livesey, F. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu302 · Cited by 22
Metadata
- Authors
- Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F. H., Remes, A. M., Koo, E. H., & Goldstein, L. S. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Salk Institute for Biological Studies (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- BD Biosciences (United States) (US)
- University of Oulu (FI)
- Corresponding author
- Goldstein, Lawrence S. B.
- ORCID
- Venue
- Nature
- Published
- 2012-01-25
- Volume
- 482
- Issue
- 7384
- Pages
- 216-220
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3338985
- OpenAlex
- W2088714934
- Cited by
- 1,253
- References
- 37
- Citations by year
- 2026: 45 · 2025: 55 · 2024: 73 · 2023: 61 · 2022: 100 · 2021: 73 · 2020: 105 · 2019: 86 · 2018: 87 · 2017: 76 · 2016: 108 · 2015: 105 · 2014: 106 · 2013: 95 · 2012: 74
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- (No Title)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (P50AG005131)
- National Institute of General Medical Sciences (T32GM008666)
- National Institute of Neurological Disorders and Stroke (P30NS047101, RC1NS068705)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD001259)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, induced pluripotent stem cells, familial Alzheimer's disease, sporadic Alzheimer's disease, amyloid-beta secretion, gamma-secretase inhibitors, beta-secretase inhibitors, phosphorylated tau, glycogen synthase kinase-3β, APP proteolytic processing, iPSC-derived neurons, patient-derived fibroblasts
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Astrocytes, Cells, Cultured, Enzyme Activation, Female, Fibroblasts, Humans, Male, Middle Aged, Models, Biological, Neurons, Peptide Fragments, Phosphoproteins, Phosphorylation, Protease Inhibitors, Endosomes, Biomarkers, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Synapsins, tau Proteins, Coculture Techniques, Glycogen Synthase Kinase 3, Amyloid Precursor Protein Secretases, Induced Pluripotent Stem Cells, Proteolysis, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
